Full Press Release Details
Ultragenyx and Kyowa Hakko Kirin Announce Submission of Burosumab's Biologics License Application in the US.
RARE
Ultragenyx and Kyowa Hakko Kirin Announce Submission of Burosumab's Biologics License Application in the US
Key Takeaway: Ultragenyx and Kyowa Hakko Kirin Announce Submission of Burosumab's Biologics License Application in the US
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+43%
120-day peak, hindsight
Typical move
2.9%
average across 6 past catalysts
Cash runway
~13 mo
Low dilution risk
Lead asset
BPS804
Phase 2 · Hypophosphatasia